Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 130

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 130
---
 5.1*           |     | Opinion of Baker McKenzie AG, Swiss counsel to NLS Pharmaceutics Ltd.                                                                                                                                                                                                                              |
| 10.1           |     | Common Shares Purchase Agreement, dated March 30, 2025, between NLS Pharmaceutics and Alpha Capital Anstalt (filed as Exhibit 99.3 to Form 6-K (File No. 001-39957) filed March 31, 2025).                                                                                                         |
| 10.2           |     | Form of Pre-Funded Warrant (filed as Exhibit 99.4 to Form 6-K (File No. 001-39957) filed March 31, 2025).                                                                                                                                                                                          |
| 23.1*          |     | Consent of PricewaterhouseCoopers AG.                                                                                                                                                                                                                                                              |
| 23.2*          |     | Consent of Marcum LLP.                                                                                                                                                                                                                                                                             |
| 23.3*          |     | Consent of Kost Forer Gabbay & Kasierer, a member of EY Global.                                                                                                                                                                                                                                    |
| 24.1*          |     | Power of Attorney (included on signature page).                                                                                                                                                                                                                                                    |
| 107*           |     | Filing Fee Table                                                                                                                                                                                                                                                                                   |

| * | Filed herewith |

<div align='center'>II-4</div>

Item 9. Undertakings

| (a) | The undersigned Registrant hereby undertakes: |

| (1) | To file, during any period                                                                          
 in which offers or sales are being made, a post-effective amendment to this registration statement: |

| (i) | To include any prospectus required                 
 by section 10(a)(3) of the Securities Act of 1933; |

| (ii) | To reflect in the prospectus                                                                                                                        
 any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)            
 which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding 
 the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed           
 that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the               
 form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume